38 Works

Additional file 1 of Long term follow-up in two siblings with Sengers syndrome: Case report

Chiara Panicucci, Maria Cristina Schiaffino, Claudia Nesti, Maria Derchi, Gianluca Trocchio, Mariasavina Severino, Nicola Stagnaro, Enrico Priolo, Federico Zara, Filippo M. Santorelli & Claudio Bruno
Supplementary Material 1

Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma

Valeria Lucarini, Ombretta Melaiu, Silvia D’Amico, Fabio Pastorino, Patrizia Tempora, Marco Scarsella, Marco Pezzullo, Adele De Ninno, Valentina D’Oria, Michele Cilli, Laura Emionite, Paola Infante, Lucia Di Marcotullio, Maria Antonietta De Ioris, Giovanni Barillari, Rita Alaggio, Luca Businaro, Mirco Ponzoni, Franco Locatelli & Doriana Fruci
Abstract Background Poor infiltration of functioning T cells renders tumors unresponsive to checkpoint-blocking immunotherapies. Here, we identified a combinatorial in situ immunomodulation strategy based on the administration of selected immunogenic drugs and immunotherapy to sensitize poorly T-cell-infiltrated neuroblastoma (NB) to the host antitumor immune response. Methods 975A2 and 9464D NB cell lines derived from spontaneous tumors of TH-MYCN transgenic mice were employed to study drug combinations able of enhancing the antitumor immune response using in...

Prevalence of familial autoimmune diseases in juvenile idiopathic arthritis: results from the international Pharmachild registry

Joeri W. van Straalen, Sytze de Roock, Gabriella Giancane, Ekaterina Alexeeva, Elena Koskova, Pablo Mesa-del-Castillo Bermejo, Francesco Zulian, Adele Civino, Davide Montin, Nico M. Wulffraat, Nicolino Ruperto & Joost F. Swart
Abstract Background Little is known about the disposition to autoimmune diseases (ADs) among children diagnosed with JIA. In this study, we provide a comprehensive overview of the prevalence of and factors associated with ADs in parents of children with juvenile idiopathic arthritis (JIA). Methods Prevalence rates of ADs and 95% Poisson confidence intervals were calculated for parents of JIA patients from the international Pharmachild registry and compared with general population prevalence rates as reported in...

Prevalence of familial autoimmune diseases in juvenile idiopathic arthritis: results from the international Pharmachild registry

Joeri W. van Straalen, Sytze de Roock, Gabriella Giancane, Ekaterina Alexeeva, Elena Koskova, Pablo Mesa-del-Castillo Bermejo, Francesco Zulian, Adele Civino, Davide Montin, Nico M. Wulffraat, Nicolino Ruperto & Joost F. Swart
Abstract Background Little is known about the disposition to autoimmune diseases (ADs) among children diagnosed with JIA. In this study, we provide a comprehensive overview of the prevalence of and factors associated with ADs in parents of children with juvenile idiopathic arthritis (JIA). Methods Prevalence rates of ADs and 95% Poisson confidence intervals were calculated for parents of JIA patients from the international Pharmachild registry and compared with general population prevalence rates as reported in...

Bone Mineral Density Reference Values in 18- to 95-Year-Old Population in Lombardy Region, Italy

Mariangela Rondanelli, Clara Gasparri, Federica Perdoni, Antonella Riva, Giovanna Petrangolini, Gabriella Peroni, Milena Anna Faliva, Maurizio Naso & Simone Perna
The aim of this study is to assess the bone mineral density (BMD) and T-score reference values in a population from 18 to 95 years old in Lombardy region, Italy. This study also investigates the association between BMD values and body mass index (BMI) divided by gender and age. The evaluation of BMD was analyzed by T-score and BMD in each site, femur, and column. A total of 10,503 patients (9,627 females and 876 males,...

Additional file 2 of Long term follow-up in two siblings with Sengers syndrome: Case report

Chiara Panicucci, Maria Cristina Schiaffino, Claudia Nesti, Maria Derchi, Gianluca Trocchio, Mariasavina Severino, Nicola Stagnaro, Enrico Priolo, Federico Zara, Filippo M. Santorelli & Claudio Bruno
Supplementary Material 2

Additional file 1 of Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer

Gennaro Ciliberto, Marco Canfora, Irene Terrenato, Chiara Agnoletto, Francesco Agustoni, Loredana Amoroso, Gustavo Baldassarre, Giuseppe Curigliano, Angelo Delmonte, Antonella De Luca, Michelangelo Fiorentino, Vanesa Gregorc, Toni Ibrahim, Chiara Lazzari, Angela Mastronuzzi, Paolo Pronzato, Armando Santoro, Giovanni Scambia, Stefania Tommasi, Andrea Vingiani, Patrizio Giacomini & Ruggero De Maria
Additional file 1: Appendix I.

Additional file 3 of Prevalence of familial autoimmune diseases in juvenile idiopathic arthritis: results from the international Pharmachild registry

Joeri W. van Straalen, Sytze de Roock, Gabriella Giancane, Ekaterina Alexeeva, Elena Koskova, Pablo Mesa-del-Castillo Bermejo, Francesco Zulian, Adele Civino, Davide Montin, Nico M. Wulffraat, Nicolino Ruperto & Joost F. Swart
Additional file 3. Prevalence rates of diseases from the “other autoimmune disease” category in parents of included JIA patients (n = 17,346).

Additional file 3 of Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study

Joeri W. van Straalen, Sytze de Roock, Gabriella Giancane, Alessandro Consolaro, Marite Rygg, Ellen B. Nordal, Nadina Rubio-Pérez, Marija Jelusic, Jaime De Inocencio, Jelena Vojinovic, Nico M. Wulffraat, Patricia C. J. Bruijning-Verhagen, Nicolino Ruperto & Joost F. Swart
Additional file 3. Extended patient characteristics at baseline.

Additional file 4 of Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study

Joeri W. van Straalen, Sytze de Roock, Gabriella Giancane, Alessandro Consolaro, Marite Rygg, Ellen B. Nordal, Nadina Rubio-Pérez, Marija Jelusic, Jaime De Inocencio, Jelena Vojinovic, Nico M. Wulffraat, Patricia C. J. Bruijning-Verhagen, Nicolino Ruperto & Joost F. Swart
Additional file 4. Stacked histograms of time intervals between start of etanercept/adalimumab therapy and baseline/follow-up measurements.

Additional file 2 of Long term follow-up in two siblings with Sengers syndrome: Case report

Chiara Panicucci, Maria Cristina Schiaffino, Claudia Nesti, Maria Derchi, Gianluca Trocchio, Mariasavina Severino, Nicola Stagnaro, Enrico Priolo, Federico Zara, Filippo M. Santorelli & Claudio Bruno
Supplementary Material 2

Long term follow-up in two siblings with Sengers syndrome: Case report

Chiara Panicucci, Maria Cristina Schiaffino, Claudia Nesti, Maria Derchi, Gianluca Trocchio, Mariasavina Severino, Nicola Stagnaro, Enrico Priolo, Federico Zara, Filippo M. Santorelli & Claudio Bruno
Abstract Background Sengers syndrome is characterized by congenital cataract, hypertrophic cardiomyopathy, mitochondrial myopathy, and lactic acidosis associated with mutations in AGK gene. Clinical course ranges from a severe fatal neonatal form, to a more benign form allowing survival into adulthood, to an isolated form of congenital cataract. Thus far few reported cases have survived the second decade at their latest examination, and no natural history data are available for the disease. Case presentation Here we...

Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer

Gennaro Ciliberto, Marco Canfora, Irene Terrenato, Chiara Agnoletto, Francesco Agustoni, Loredana Amoroso, Gustavo Baldassarre, Giuseppe Curigliano, Angelo Delmonte, Antonella De Luca, Michelangelo Fiorentino, Vanesa Gregorc, Toni Ibrahim, Chiara Lazzari, Angela Mastronuzzi, Paolo Pronzato, Armando Santoro, Giovanni Scambia, Stefania Tommasi, Andrea Vingiani, Patrizio Giacomini & Ruggero De Maria
Abstract Background Molecular tumor boards (MTBs) match molecular alterations with targeted anticancer drugs upon failure of the available therapeutic options. Special and local needs are most likely to emerge through the comparative analysis of MTB networks, but these are rarely reported. This manuscript summarizes the state-of-art of 16 active Italian MTBs, as it emerges from an online survey curated by Alliance Against Cancer (ACC). Main text Most MTBs (13/16) are exclusively supported through local Institutional...

Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer

Gennaro Ciliberto, Marco Canfora, Irene Terrenato, Chiara Agnoletto, Francesco Agustoni, Loredana Amoroso, Gustavo Baldassarre, Giuseppe Curigliano, Angelo Delmonte, Antonella De Luca, Michelangelo Fiorentino, Vanesa Gregorc, Toni Ibrahim, Chiara Lazzari, Angela Mastronuzzi, Paolo Pronzato, Armando Santoro, Giovanni Scambia, Stefania Tommasi, Andrea Vingiani, Patrizio Giacomini & Ruggero De Maria
Abstract Background Molecular tumor boards (MTBs) match molecular alterations with targeted anticancer drugs upon failure of the available therapeutic options. Special and local needs are most likely to emerge through the comparative analysis of MTB networks, but these are rarely reported. This manuscript summarizes the state-of-art of 16 active Italian MTBs, as it emerges from an online survey curated by Alliance Against Cancer (ACC). Main text Most MTBs (13/16) are exclusively supported through local Institutional...

Additional file 2 of Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study

Joeri W. van Straalen, Sytze de Roock, Gabriella Giancane, Alessandro Consolaro, Marite Rygg, Ellen B. Nordal, Nadina Rubio-Pérez, Marija Jelusic, Jaime De Inocencio, Jelena Vojinovic, Nico M. Wulffraat, Patricia C. J. Bruijning-Verhagen, Nicolino Ruperto & Joost F. Swart
Additional file 2. Characteristics of included and excluded patients.

Additional file 4 of Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study

Joeri W. van Straalen, Sytze de Roock, Gabriella Giancane, Alessandro Consolaro, Marite Rygg, Ellen B. Nordal, Nadina Rubio-Pérez, Marija Jelusic, Jaime De Inocencio, Jelena Vojinovic, Nico M. Wulffraat, Patricia C. J. Bruijning-Verhagen, Nicolino Ruperto & Joost F. Swart
Additional file 4. Stacked histograms of time intervals between start of etanercept/adalimumab therapy and baseline/follow-up measurements.

Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study

Joeri W. van Straalen, Sytze de Roock, Gabriella Giancane, Alessandro Consolaro, Marite Rygg, Ellen B. Nordal, Nadina Rubio-Pérez, Marija Jelusic, Jaime De Inocencio, Jelena Vojinovic, Nico M. Wulffraat, Patricia C. J. Bruijning-Verhagen, Nicolino Ruperto & Joost F. Swart
Abstract Background Etanercept (ETN) and adalimumab (ADA) are considered equally effective biologicals in the treatment of arthritis in juvenile idiopathic arthritis (JIA) but no studies have compared their impact on patient-reported well-being. The objective of this study was to determine whether ETN and ADA have a differential effect on patient-reported well-being in non-systemic JIA using real-world data. Methods Biological-naive patients without a history of uveitis were selected from the international Pharmachild registry. Patients starting ETN...

Additional file 1 of Long term follow-up in two siblings with Sengers syndrome: Case report

Chiara Panicucci, Maria Cristina Schiaffino, Claudia Nesti, Maria Derchi, Gianluca Trocchio, Mariasavina Severino, Nicola Stagnaro, Enrico Priolo, Federico Zara, Filippo M. Santorelli & Claudio Bruno
Supplementary Material 1

Additional file 5 of Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study

Joeri W. van Straalen, Sytze de Roock, Gabriella Giancane, Alessandro Consolaro, Marite Rygg, Ellen B. Nordal, Nadina Rubio-Pérez, Marija Jelusic, Jaime De Inocencio, Jelena Vojinovic, Nico M. Wulffraat, Patricia C. J. Bruijning-Verhagen, Nicolino Ruperto & Joost F. Swart
Additional file 5. Results from follow-up measurements for the unmatched cohort.

Additional file 1 of Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma

Valeria Lucarini, Ombretta Melaiu, Silvia D’Amico, Fabio Pastorino, Patrizia Tempora, Marco Scarsella, Marco Pezzullo, Adele De Ninno, Valentina D’Oria, Michele Cilli, Laura Emionite, Paola Infante, Lucia Di Marcotullio, Maria Antonietta De Ioris, Giovanni Barillari, Rita Alaggio, Luca Businaro, Mirco Ponzoni, Franco Locatelli & Doriana Fruci
Additional file 1: Fig. S1. Flow-cytometry analysis of tumor-infiltrating immune cells in mouse NB models. Fig. S2. Immune content of cisplatin- and vincristine-treated 975A2 tumors. Fig. S3. Immune content of drug-treated 975A2 tumors. Fig. S4. Effect of anti-TGFβ treatment on immune content of 975A2 tumors. Fig. S5. Effect of combined drug treatment on the recall and activation of CD8+ T cells and NK cells. Fig. S6. Treatment of mitoxantrone in combination with TGFβ and PD-1...

Additional file 1 of Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma

Valeria Lucarini, Ombretta Melaiu, Silvia D’Amico, Fabio Pastorino, Patrizia Tempora, Marco Scarsella, Marco Pezzullo, Adele De Ninno, Valentina D’Oria, Michele Cilli, Laura Emionite, Paola Infante, Lucia Di Marcotullio, Maria Antonietta De Ioris, Giovanni Barillari, Rita Alaggio, Luca Businaro, Mirco Ponzoni, Franco Locatelli & Doriana Fruci
Additional file 1: Fig. S1. Flow-cytometry analysis of tumor-infiltrating immune cells in mouse NB models. Fig. S2. Immune content of cisplatin- and vincristine-treated 975A2 tumors. Fig. S3. Immune content of drug-treated 975A2 tumors. Fig. S4. Effect of anti-TGFβ treatment on immune content of 975A2 tumors. Fig. S5. Effect of combined drug treatment on the recall and activation of CD8+ T cells and NK cells. Fig. S6. Treatment of mitoxantrone in combination with TGFβ and PD-1...

sj-docx-1-jmh-10.1177_15579883221119363 – Supplemental material for Bone Mineral Density Reference Values in 18- to 95-Year-Old Population in Lombardy Region, Italy

Mariangela Rondanelli, Clara Gasparri, Federica Perdoni, Antonella Riva, Giovanna Petrangolini, Gabriella Peroni, Milena Anna Faliva, Maurizio Naso & Simone Perna
Supplemental material, sj-docx-1-jmh-10.1177_15579883221119363 for Bone Mineral Density Reference Values in 18- to 95-Year-Old Population in Lombardy Region, Italy by Mariangela Rondanelli, Clara Gasparri, Federica Perdoni, Antonella Riva, Giovanna Petrangolini, Gabriella Peroni, Milena Anna Faliva, Maurizio Naso and Simone Perna in American Journal of Men's Health

Additional file 1 of Prevalence of familial autoimmune diseases in juvenile idiopathic arthritis: results from the international Pharmachild registry

Joeri W. van Straalen, Sytze de Roock, Gabriella Giancane, Ekaterina Alexeeva, Elena Koskova, Pablo Mesa-del-Castillo Bermejo, Francesco Zulian, Adele Civino, Davide Montin, Nico M. Wulffraat, Nicolino Ruperto & Joost F. Swart
Additional file 1. Classification of treatment center countries of JIA patients into geographic regions.

Additional file 2 of Prevalence of familial autoimmune diseases in juvenile idiopathic arthritis: results from the international Pharmachild registry

Joeri W. van Straalen, Sytze de Roock, Gabriella Giancane, Ekaterina Alexeeva, Elena Koskova, Pablo Mesa-del-Castillo Bermejo, Francesco Zulian, Adele Civino, Davide Montin, Nico M. Wulffraat, Nicolino Ruperto & Joost F. Swart
Additional file 2. Classification of reported autoimmune diseases in parents of included JIA patients.

Additional file 3 of Prevalence of familial autoimmune diseases in juvenile idiopathic arthritis: results from the international Pharmachild registry

Joeri W. van Straalen, Sytze de Roock, Gabriella Giancane, Ekaterina Alexeeva, Elena Koskova, Pablo Mesa-del-Castillo Bermejo, Francesco Zulian, Adele Civino, Davide Montin, Nico M. Wulffraat, Nicolino Ruperto & Joost F. Swart
Additional file 3. Prevalence rates of diseases from the “other autoimmune disease” category in parents of included JIA patients (n = 17,346).

Registration Year

  • 2022
    38

Resource Types

  • Text
    26
  • Collection
    12

Affiliations

  • Istituto Giannina Gaslini
    38
  • University of Genoa
    30
  • Utrecht University
    20
  • University Medical Center Utrecht
    20
  • Wilhelmina Children's Hospital
    20
  • University of Niš
    12
  • University of Zagreb
    12
  • Hospital Universitario 12 de Octubre
    12
  • UiT The Arctic University of Norway
    12
  • St Olav's University Hospital
    12